Physician profile
Andrew E Filderman
NPI 1093705766
$209,687.58
in general payments reported to CMS, 2019-2025
17 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $37K · 2021: $45K · 2022: $9,847 · 2023: $46K · 2024: $24K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Travel and Lodging: $3,619 · Food and Beverage: $2,043 · Consulting Fee: $150 · Education: $8.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,075.00 |
| Travel and Lodging | $3,618.70 |
| Food and Beverage | $2,043.11 |
| Consulting Fee | $150.00 |
| Education | $8.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $160,661.46 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals Lp | $43,186.91 | 2019-2025 | Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,075.53 | 2019-2021 | |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Genentech USA, INC. | $282.12 | 2019-2020 | |
| Genzyme Corporation | $232.74 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $222.22 | 2019-2025 | |
| Grifols USA, LLC | $83.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.83 | 2019-2021 | |
| Philips North America LLC | $64.71 | 2019 | |
| Harmony Biosciences LLC | $57.34 | 2020-2021 | |
| Circassia INC. | $53.00 | 2019-2020 | |
| Shire North American Group INC | $27.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.59 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $16.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Filderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.